Furthermore, Kaplan-Meier survival analysis was performed to examine the predictive value of serum L1CAM level at baseline, and the results indicated the NSCLC patients with low serum L1CAM levels had better PFS and OS [PFS: Low (n = 17), Median PFS = 166 days vs. High (n = 11), Median PFS = 44 days, P = 0.002; OS: Low (n = 17), Median OS = 259 days vs. High (n = 11), Median OS = 163 days, P = 0.038] (Figures 4D,E). This evidence concerns the gene L1CAM and non-small cell lung carcinoma.